Valhi, Inc.(VHI)Earnings, Financials & Key RatiosValhi, Inc. (VHI) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the forward P/E of 4.25 suggests potential undervaluation, the extreme volatility in operating cash flow and the recent $53.2 million net loss in 2025Q4 warrant a cautious approach until margins stabilize.
Valhi, Inc. (VHI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Valhi, Inc. (VHI) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.07vs $0.77-90.9% | $560Mvs $560M+0.0% |
| Q2 2026 | Mar 10, 2026 | $1.86vs $0.86-315.0% | $495Mvs $495M+0.0% |
| Q4 2025 | Nov 6, 2025 | $0.33vs $0.83-139.7% | $504M |
| Q3 2025 | Aug 7, 2025 | $0.03vs $0.76-96.1% | $572M |
Recent stock market news and headlines for Valhi, Inc. (VHI)
Discover why Zacks, being the first on Wall Street to initiate coverage of the stock, rates Valhi as "Underperform." Explore how VHI's pricing pressure, weak demand and rising costs could weigh on earnings and limit upside potential.
TORONTO, June 16, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today that Novari Health, a VitalHub company, has executed agreements to implement wait list and referral management software technologies at Sunnybrook Health Sciences Centre and across the northern region of British Columbia. Sunnybrook joins hospitals, regional health authorities, and health systems in Canada, Australia and the United Kingdom that have implemented Novari solutions to improve access to care. The Novari solutions are being leveraged in British Columbia to help modernize the region's delivery of surgical, diagnostic imaging, and laboratory services.
Key metrics vs top competitors for Valhi, Inc. (VHI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.30 | $376.42M | -6.58 | -1.32% | -2.77% | -4.2% | 2.4% | |
| $5.97 | $686.87M | -6.22 | -1.47% | -7.12% | -17% | — | |
| $10.97 | $1.91B | -6.90 | -5.85% | -5.69% | -8.14% | — | |
| $18.85 | $2.83B | -7.36 | 0.45% | -7.06% | -163.42% | — | |
| $6.03 | $294.64M | -7.83 | 8.46% | -21.53% | -8.73% | — | |
| $11.88 | $7.23B | -118.80 | 23.67% | 0.17% | 1.11% | — |
Valhi, Inc. (VHI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Valhi, Inc. (VHI) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 7, 2026·SEC
Mar 10, 2026·SEC
Mar 5, 2026·SEC
Get notified when VHI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Valhi, Inc. (VHI) stock FAQ — growth, dividends, profitability & financials explained
Valhi, Inc. (VHI) reported $2.10B in revenue for fiscal year 2025. This represents a 76% increase from $1.19B in 1996.
Valhi, Inc. (VHI) saw revenue decline by 1.3% over the past year.
Valhi, Inc. (VHI) reported a net loss of $72.5M for fiscal year 2025.
Yes, Valhi, Inc. (VHI) pays a dividend with a yield of 2.40%. This makes it attractive for income-focused investors.
Valhi, Inc. (VHI) has a return on equity (ROE) of -4.2%. Negative ROE indicates the company is unprofitable.
Valhi, Inc. (VHI) generated $29.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
